Merck MRK, known as MSD outside the United States and Canada,
issued the following statement regarding the decision of the U.S. Court
of Appeals for the Federal Circuit. The decision validated the patent
for CUBICIN® (daptomycin for injection) that expires on June
15, 2016, but invalidated four patents with expiration dates in 2019 and
2020.
The company is reviewing the decision and is considering its next steps,
which may include seeking further review at the Federal Circuit or
Supreme Court.
About Merck
Today's Merck is a global health care leader working to help the world
be well. Merck is known
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in